IRCT2017092036286N1已完成未知
The effect of inhaled beclomethasone with or without montelukast in the control of pediatric persistent asthma
Vice- Chancellor for Research Technology Affairs, Babol University of Medical Sciences0 个研究点目标入组 80 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 years 至 10 years（—）
- 性别
- All
入选标准
- •Pediatrics aged 6 to 10 years; Pediatrics with persistent asthma symptoms; referred to the Center during the study;
- •Exclusion criteria: Pediatrics with lung infections; Pediatrics any underlying illness such as simultaneous cardiac disease; Antihistamine use; Having any illness; Taking other medications;
排除标准
- 未提供
研究者
相似试验
已完成
2 期
assessment of applying beclomethasone spray and fluticasone spray on endotracheal tube cuff on postoperative sore throatRelation of applying beclomethasone spray and fluticasone spray on endotracheal tube cuff with postoperative sore throat in patient with surgery.Acute pharyngitis, unspecifiedIRCT2013012812007N2Kerman University of Medical Sciences90
已完成
不适用
Trial of Beclomethasone dipropionate versus Budesonide inhaler therapy in mild persistent asthma in childreCTRI/2013/03/003495A85
已完成
2 期
Comparing the effect of injectable betamethasone with oral betamethasone in mandibular wisdom teeth surgery.Impacted wisdom teeth.Impacted teethIRCT20180117038415N2Tabriz University of Medical Sciences24
尚未招募
不适用
Comparison of different steroids in post PRK IOPPRK candidate.Glaucoma secondary to drugsIRCT20190207042650N1Tehran University of Medical Sciences240
进行中（未招募）
1 期
Effect of fixed combination of beclomethasone dipropionate/formoterol fumarate (BDP/FF), as reliever, upon exhaled nitric oxide in asthma. FENOMENO study (Fractional Exhaled Nitric Oxide-Multiple Expiration flow of NO). A single-centre, placebo controlled, randomized, double blind, cross-over study - FenomenoModerate asthmaMedDRA version: 9.1 Level: LLT Classification code 10003553 Term: AsthmaEUCTR2007-004377-26-GBChiesi Farmaceutici S.p.A.20